Akelos, a New York-based biopharmaceutical company, was founded to address the opioid epidemic by developing innovative non-opioid drugs for the treatment of neuropathic pain. The company's core mission is to translate cutting-edge scientific research into effective treatments for chronic and neuropathic pain, aiming to provide safer alternatives to opioids. Akelos is currently focused on advancing two drug candidates in pre-clinical development, with a strong emphasis on non-narcotic solutions.
Notable affiliates include Dr. Steven Fox, who plays a pivotal role in the company's research and development efforts. Akelos has established a significant research collaboration to develop and commercialize a novel non-opioid anti-hyperalgesic drug. This partnership underscores the company's commitment to addressing unmet medical needs. Akelos has made substantial strides in the biopharmaceutical industry, contributing to the broader effort to mitigate the opioid crisis through innovative pain management solutions.
